Atrium Therapeutics, Inc. Common Stock

Atrium Therapeutics reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying treatment for PRKAG2 syndrome. It also collected a second milestone payment from its cardiovascular partnership with Bristol Myers Squibb. None of that changes the fact that Atrium still spends far more than it brings in. Second-quarter collaboration revenue came in at $3 million, a fraction of the $15.3 million spent on research and development and the $10.3 million spent on general and administrative costs, a combined $25.6 million in expenses against a sliver of revenue. With $263.9 million in cash, cash equivalents, and short-term investments as of June 30, and that milestone payment included, the company says it can fund operations through mid-2028. Hedge fund ownership of Atrium fell from 37 funds to 30 heading into this report, a pullback that suggests some institutional money trimmed positions ahead of the clinical and financial update.